N/A
N=100
Meaningful Use of Technology to Improve Health Care Delivery
Contraceptive Behavior
Bottom Line
View on ClinicalTrials.gov: NCT01641380 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcome: Primary: Appointment Adherence (Efficacy) — 34; 28 participants — p=<.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Text Messaging Intervention (Behavioral)
- Age
- Pediatric, Adult · 13+ yrs
- Sex
- Female
- Sponsor
- Johns Hopkins University
- Primary completion
- Mar 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Appointment Adherence (Efficacy) |
34; 28 | <.05 sig |
| PRIMARY Responsiveness to Appointment Messages |
38; 34 | — |
| SECONDARY Proportion of Patients Satisfied With Messaging Service |
25; 24 | — |
Summary
While there have been major declines in teenage pregnancy around the country, Baltimore, Maryland has continued to experience increases over the last several years. Access and adherence to contraception has been found to be a major contributor to declines in teen pregnancy worldwide. The aim of this proof of concept pilot project is to determine preliminary efficacy of the DepoText Intervention. We will randomize urban adolescent girls who have elected Depo-Provera for ongoing contraception to receive either standard counseling and clinic appointment reminders or a text messaging (DepoTEXT) follow-up intervention. Participants in the DepoTEXT intervention will receive reminders for clinic visits and encouraging messages each month for STI prevention. The primary outcome is the preliminary efficacy for improving appointment adherence.
Eligibility Criteria
Inclusion Criteria
- Selected Depo-Provera for ongoing contraception
- Have a cell phone with text messaging capacity for personal use, and
- Agree to be randomized
Exclusion Criteria
- Adolescent girls using other forms of contraception
- Adolescents who do not have a cell phone w/ text messaging capability for personal use
Data sourced from ClinicalTrials.gov (NCT01641380). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.